In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
Low levels of early HIV testing among children of sex workers living with HIV in Cameroon: the importance of engagement in health services
on June 19, 2019 at 7:15 pm
In 2015, over 4000 babies were born with HIV in the Central African country of Cameroon. The best estimates of life expectancy at birth suggest that these children will only live on average for ... […]
HIV prevention drug services expanding in some counties
on June 19, 2019 at 3:54 pm
CAIRO, Ill. (AP) — The Southern Illinois University School of Medicine and the Southern Seven Health Department are working to expand HIV prevention drug services to people in some rural areas. The ... […]
Study reveals global disparities in cervical cancer rates among women with HIV
on June 19, 2019 at 8:46 am
A new International Journal of Cancer study indicates that rates of invasive cervical cancer (ICC) are particularly high in women living with HIV in South Africa or Latin America. For the study ... […]
Block party will mark National HIV Testing Day on June 29
on June 19, 2019 at 8:17 am
Block party will mark National HIV Testing Day on June 29 DOH-Leon is taking steps to decrease new HIV infections and HIV-related deaths. Check out this story on tallahassee.com: ... […]
People who inject drugs helped investigate factors influencing susceptibility to HIV
on June 19, 2019 at 7:36 am
In recent years, the HIV infection rate in Estonia has continued to be around 200 new cases each year, which is still one of the highest incidence rates per 100,000 inhabitants in Europe. ... […]
How I Learned to Let Go of My Shame and Embrace Being HIV-Positive (Column)
on June 19, 2019 at 7:00 am
I knew better. At least I was supposed to know better. I was just coming out of the closet in the late ’80s when both of my mother’s brothers died of AIDS. It was the darkest days of the epidemic. ... […]
HIV, Hep A, measles. CDC director shares his priority list of diseases to wipe out in Florida.
on June 19, 2019 at 5:18 am
Florida has seen cases of almost every infectious in the last six months including measles, mumps, Hepatitis A and HIV. With some diseases, the number of new cases is alarming and health officials are ... […]
Global Human Immunodeficiency Virus (HIV) drugs market size is expected to surpass US$ 30 billion by 2025
on June 19, 2019 at 2:32 am
Jun 19, 2019 (AmericanNewsHour via COMTEX) -- Global Human Immunodeficiency Virus (HIV) Drugs Market 2019 - 2025: Top 22 Drugs Analysis, Key Trends, Players and Forecasts" presents an in-depth ... […]
Ugandan Health Workers Warn HIV-Positive Refugees Poorly Tracked
on June 19, 2019 at 1:43 am
ADJUMANI, UGANDA - Uganda hosts Africa’s largest refugee population, about one and a quarter million, mostly South Sudanese. Health workers warn that the refugees infected with HIV, the virus that ... […]
Prophylactic HIV drugs Market Estimated to Experience a Hike in Growth by 2029
on June 19, 2019 at 1:29 am
Jun 19, 2019 (MARKITWIRED via COMTEX) -- Prophylactic HIV drugs: Market Insights HIV is one of the leading cause of death worldwide affecting millions of people. HIV has become the chief contributor ... […]
via Google News and Bing News